DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rasagiline
Rasagiline
(12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
Parkinson Disease-Associated Cognitive Impairment
Azilect, INN-Rasagiline
3 Drugs That May Cause Delirium Or Problem Behaviors CARD 03 19 12 JUSTIFIED.Pub
Drug-Induced Movement Disorders
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’S Disease
Re-Submission Rasagiline 1Mg Tablet (Azilectò) (No
Guideline for Preoperative Medication Management
Safinamide for Parkinson's Disease
Part I: Synthesis of Functionalized Bile Acids Towards The
Summary Review
Identification of Novel Monoamine Oxidase B Inhibitors from Ligand Based Virtual Screening
New Medicine Recommendation Safinamide (Xadago ) 50Mg And
Third Quarter 2017 Update
A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
FIRST of 2 PARTS Web Video at Currentpsychiatry.Com Dr
Medications to Be Avoided Or Used with Caution in Parkinson's Disease
Rasagiline NDC 0378- -93 Dispense in a Tight, Light-Resistant Mesylate Equivalent to 0.5 Mg 1270 Container As Defined in the USP of Rasagiline
Top View
Clinical Outcome Assessment (Coa) Compendium
Pharmacological Aspects of the Neuroprotective Effects Of
Methyldopa | Memorial Sloan Kettering Cancer Center
Rasagiline ESCA: for the Treatment of Parkinson's Disease AREAS of RESPONSIBILITY for the SHARING of CARE
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations the PRESTO Study
Sumatriptan (Injection) Medical Facts from Drugs.Com
Activation of Tyrosine Kinase Receptor Signaling Pathway by Rasagiline
Formulary and Program Updates Effective 8/1/18
Download Leaflet View the Patient Leaflet in PDF Format
Azilect Prescribing Information
Treatment of Parkinson Disease with Motor Fluctuations And
FDA Approved Labeling Text for NDA 021641/S-002/S-003/S-004/S-005/S-007/S-008/S-010 Dated 12/9/09
Azilect) Reference Number: HIM.PA.89 Effective Date: 12.14 Last Review Date: 08.20 Line of Business: HIM Revision Log
Sharp Health Plan 2020 Formulary List of Covered Prescription Drugs
Neuroprotective Properties of Green Tea (Camellia Sinensis) in Parkinson’S Disease: a Review
Hydride Abstraction As the Rate-Limiting Step of The
Sembragiline: a Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’S Disease S
Therapeutic Drug Class